WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon 04 March 2010
Pfizer's Prevnar 13 Recommended by CDC's Advisory Committee On Immunization Practices 25 February 2010
Lilly, Merck, And Pfizer Announce the Formation of the Asian Cancer Research Group, Inc. 24 February 2010
Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness 09 February 2010
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results 04 February 2010
New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas 28 January 2010
Pfizer and Strides Arcolab to Collaborate on Generic Products 07 January 2010
Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine 02 January 2010
FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations 21 December 2009
Takeda and Pfizer to Co-Promote Takeda's Actos® for the Treatment of Type 2 Diabetes in China 16 December 2009
Pfizer Extends Commitment to Help Unemployed Americans 11 December 2009
Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System 10 December 2009
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment 02 December 2009
FDA Advisory Committee Finds Data Support SPIRIVA® HandiHaler® 20 November 2009
Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon 04 November 2009
Pfizer Reports Third-Quarter 2009 Results 22 October 2009
Pfizer And Wyeth Become One: Working Together For A Healthier World™ 16 October 2009
Pfizer Completes Acquisition Of Wyeth 16 October 2009
Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau 15 October 2009
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry 09 October 2009
  • Start
  • Prev
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
  • End
Health data interoperability: Opportunities and threats

Business & Industry

  • Amgen successfully completes acquisition of Five Prime Therapeutics
  • GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
  • Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
  • Pfizer and BioNTech request regulatory agencies expand emergency use of their COVID-19 vaccine to adolescents
  • Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001

Research & Development

  • SARS-CoV-2: New findings on the persistence of neutralizing antibodies
  • Massive fragment screen points way to new SARS-CoV-2 inhibitors
  • B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
  • COVID-19 causes 'unexpected' cellular response in the lungs
  • Clinical trial completion rates decline during COVID-19 pandemic
  • Study identifies possible COVID-19 drugs - including several that are FDA-approved
  • COVID-19 convalescent plasma with greater antibody levels is safe and shows promise

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
  • Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
  • AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
  • EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
  1. You are here:  
  2. Home
  3. Pfizer

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.